Market Place
Sourcing Support
NICE recommends Chiesi’s Elfabrio for adults with Fabry disease
05 Sep 2023 //
PM LIVE
Protalix & Chiesi gain positive opinion for pegunigalsidase alfa
06 Mar 2023 //
PHARMATIMES
CHMP recommends first pegylated enzyme for Fabry disease
27 Feb 2023 //
EUROPEAN PHARMACEUTICAL REVIEW
Chiesi & Protalix Receive Positive CHMP Opinion for Pegunigalsidase Alfa
25 Feb 2023 //
BIOSPACE
Protalix & Chiesi Announce FDA Acceptance of BLA for Pegunigalsidase Alfa
05 Dec 2022 //
PRNEWSWIRE
Chiesi and Protalix announce Phase III data from BRIGHT study in Fabry disease
19 Mar 2022 //
THEPHARMALETTER
Protalix BioTherapeutics to Participate in the 18th Annual WORLDSymposium™ 2022
03 Feb 2022 //
PRNEWSWIRE
Protalix sees a path for Fabry resubmission down the line
11 Oct 2021 //
FIERCEBIOTECH
Chiesi Global Rare Diseases Announces First Patient Treated in Expanded Program
24 Dec 2020 //
GLOBENEWSWIRE
Chiesi Global Rare Diseases Announces First Patient Treated in Expanded
24 Dec 2020 //
GLOBENEWSWIRE
Protalix and Chiesi Global Rare Diseases Announce Submission of Biologics
27 May 2020 //
PRNEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.